News Lilly grabs first-ever FDA nod for a sleep apnoea drug Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea, which affects millions in the US.
Digital How measurement technology can advance sleep monitoring in c... As of 2024, more than one-third of American adults don't get enough sleep, and sleep satisfaction levels are worryingly low.
News Sanofi pays $180m for rights to Kali autoimmune drug Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.